Xaliproden

Summary

Xaliproden (CHEMBL1512580) is a phase-3 clinical-stage small-molecule serotonergic agonist (ATC N07XX03); indicated across 2 conditions including colorectal neoplasm and alzheimer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: N07XX03
• Indications: 2 conditions
• Clinical trials: 4
• Chemistry: 381.4 Da · C24H22F3N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1512580
Name	Xaliproden
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	128919
ChEBI	CHEBI:48520
ATC	N07XX03
Molecular formula	C24H22F3N
Molecular weight	381.4
InChIKey	WJJYZXPHLSLMGE-UHFFFAOYSA-N

SMILES: C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC4=CC=CC=C4C=C3

IUPAC name: 1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine

ChEBI definition: A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine which is substituted on the nitrogen by a 2-(2-naphthyl)ethyl group and at position 4 by a m-trifluoromethylphenyl group.

Pharmacological roles (ChEBI): serotonergic agonist.

Also known as: SR 57746, SR-57746, SR57746, Xaliproden, Xaliprodene, Xaliprodeno, SID50112829, SID50112828, XALIPRODEN, xaliproden

Parent form; salt/anhydrous children: CHEMBL3183486

Patent coverage: 881 distinct patent families (3,264 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,183 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
colorectal neoplasm	3	MONDO:0005335	EFO:0004142
Alzheimer disease	3	MONDO:0004975	MONDO:0004975

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE3	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00103649	PHASE3	COMPLETED	18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer’s Type
NCT00104013	PHASE3	COMPLETED	Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer’s Type
NCT00305188	PHASE3	COMPLETED	Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
NCT00603577	PHASE3	TERMINATED	Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).